Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, an endogenous tetrapeptide reported to stimulate phagocytosis in macrophages and microglia and to bind the single-pass transmembrane receptor neuropilin-1 [1]. The remaining three residues, Pro-Gly-Pro, are a synthetic C-terminal extension. Selank is therefore best understood not as a novel scaffold but as tuftsin plus a proline-rich tail: the tuftsin segment is the part of the sequence that has an independently characterized receptor, and what the three added residues contribute is not stated by any source retrieved for this guide.

That framing matters when reading the literature, because much of what is claimed for Selank is inherited by association from tuftsin, and the two have not been characterized to the same depth. Tuftsin has an identified receptor and a mapped signaling route. Selank does not.

Identity and characterization

The identity figures below are the ones Echo Peptides publishes on the product page and holds in its verified compound map. They are reproduced here so a guide and a product page cannot drift apart.

Three prolines in seven residues is the dominant structural fact. Proline constrains the backbone and removes amide hydrogens, so a peptide this proline-dense has limited capacity to form regular secondary structure, and no high-resolution conformation appears in the retrieved literature. Papers that work with Selank characterize it chromatographically — HPLC is used to establish purity of the material before receptor work [2] — rather than by any solved structure. For laboratory purposes, identity is established by mass and retention behavior, not by conformation.

One published mechanistic detail depends on the sequence being read as segments rather than as a whole. In serum enzymology, pentapeptide fragments of Selank retained inhibitory activity while tri-, tetra- and hexapeptide fragments did not [6]. In immune gene-expression work, the dipeptide Gly-Pro reproduced much of the parent peptide's expression profile [10]. Both results argue that fragments of this molecule are not inert, which complicates any attempt to attribute an observed readout to the intact heptapeptide.

A second characterization route in this literature is isotopic rather than spectroscopic. Selank has been prepared evenly labeled with tritium by high-temperature solid-phase catalytic isotope exchange, at specific radioactivities in the range of 50–150 Ci/mmol, with the label distributed across every amino acid residue [7]. Even labeling is the point: it allows essentially all products of enzymatic hydrolysis to be detected and quantified simultaneously after chromatographic separation, instead of only those fragments that happen to retain a single labeled residue. Anyone planning degradation or distribution work on this molecule should know that this is the established analytical approach for it.

Mechanism as studied

GABAergic modulation, measured mostly indirectly

The most direct binding data come from a radioligand study on isolated brain-cell plasma membranes, in which Selank altered tritiated GABA binding in a manner the authors interpreted as positive allosteric modulation. In the same system, combining Selank with some benzodiazepines produced an effect that was not additive and that differed from either substance alone, and Selank blocked the modulatory activity of diazepam and of olanzapine; the authors concluded that the binding sites are apparently not identical but may partially overlap [2]. This is a membrane-preparation binding experiment and a hypothesis the authors state as such, not a resolved binding site.

Electrophysiology gives a second, independent readout. Applied to rat hippocampal slices, Selank increased the amplitude and discharge rate of spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons; in some neurons the increase was preceded by a transient decrease, and across the 1–8 μM range tested the effect showed no significant concentration dependence [3]. A flat concentration-response over nearly an order of magnitude is unusual for a receptor-mediated action and is worth holding onto when reading stronger mechanistic summaries elsewhere.

Expression studies point the same general direction with weaker specificity. In rat frontal cortex, a panel of 84 genes involved in neurotransmission — GABA receptor subunits, transporters, ion channels, dopamine and serotonin receptors — showed changes in 45 genes one hour and 22 genes three hours after administration of Selank or of GABA, and at the one-hour point the changes produced by Selank correlated positively with those produced by GABA [4].. The authors read this as a complex, distributed effect on nerve cells consistent with allosteric modulation of the GABAergic system.

The corresponding in vitro experiment did not reproduce it. In cultured IMR-32 neuroblastoma cells, Selank alone produced no change in the mRNA levels of the 84 GABAergic and neurotransmission genes assayed. It did, however, nearly abolish the expression changes GABA produced on its own, and combining it with olanzapine altered more genes than olanzapine alone [5]. The honest reading is that Selank had no direct transcriptional effect in that cell line and acted only as a modifier of another ligand's effect — which is evidence for interaction with GABAergic signaling and evidence against a direct transcriptional mechanism, in the same experiment.

Peptidase inhibition

A separate and more concretely quantified mechanism is enzyme inhibition. In human serum, Selank inhibited enkephalin-degrading enzymes with an IC50 of 20 μM, alongside Semax at 10 μM, and both were more potent in that assay than puromycin or bacitracin [6]. Because the enzymes concerned degrade regulatory peptides generally and not enkephalins alone, the authors suggested that one of the mechanisms of Selank's biological activity is related to this inhibitory activity [6]. That would be an indirect route: prolonging the life of other peptides rather than acting on a receptor of its own. Note the concentration: 20 μM is a biochemical-assay figure, and nothing in that paper establishes that such concentrations are reached anywhere in a living system.

Neurotrophin and immune readouts

Selank has been reported to regulate BDNF expression in rat hippocampus in vivo [8]. A later study measured BDNF content in hippocampus and prefrontal cortex ex vivo in rats and found that Selank prevented an ethanol-induced increase in BDNF [9]. The direction of change is therefore context-dependent, and summaries that describe Selank simply as "raising BDNF" are not supported by the second of these papers.

On the immune side, real-time PCR in mouse spleen tracked four inflammation-related transcripts — C3, Casp1, Il2rg and Xcr1 — and found a roughly three-fold fall in C3 mRNA within thirty minutes, a wave-like change in Casp1, and early changes in Il2rg followed by a reduction in Xcr1 [10]. The dipeptide Gly-Pro produced largely coincident profiles, which the authors suggested might indicate an active contribution of the dipeptide to the final effect of Selank.

The receptor question

Tuftsin's own mechanism is comparatively well defined: it binds neuropilin-1, signals through TGFβ receptor-1 as a co-receptor, promotes Smad3 phosphorylation and reduces Akt phosphorylation, and the inhibitor EG00229 prevents its binding [1].. It would be reasonable to hypothesize that the tuftsin portion of Selank engages the same receptor. No study located in this review demonstrates that. The Selank literature has not reported a direct neuropilin-1 binding measurement, a competition experiment against tuftsin, or an EG00229 block of a Selank effect. The tuftsin receptor is a plausible starting point for work that has not been done, not a described mechanism of this compound.

Model systems in which it has actually been examined

Nearly the entire experimental record sits in rodents and rodent-derived preparations, and a large share of it originates from a small number of affiliated laboratories.

  • Rat hippocampal slices — spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons, 1–8 μM [3].
  • Isolated brain-cell plasma membranes — tritiated GABA radioligand binding [2].
  • IMR-32 human neuroblastoma cells — qPCR of 84 GABAergic and neurotransmission genes [5].
  • Human serum, cell-free — enkephalin-degrading enzyme activity [6].
  • Rat frontal cortex and hippocampus — transcript panels and BDNF content [4, 8, 9].
  • Mouse spleen — inflammation-related transcripts [10].
  • Rat behavioral assays — elevated plus maze under unpredictable chronic mild stress, alone and combined with diazepam [11]; object recognition in ethanol-exposed animals [9].
  • Mouse embryonic stem cells and their derivatives — proliferation, survival and differentiation [12].

Two of these deserve their unflattering details preserved. In the elevated plus maze study, a course of the test substances shifted the behavioral indices toward deterioration even in animals not exposed to chronic stress, though the changes after a course of Selank were less pronounced; individual administration of Selank was the most effective at reducing the deterioration the course itself produced, while the combination with diazepam was the most effective under chronic stress [11]. And in mouse embryonic stem cells, Selank produced no significant effect on differentiation into mature neurons but reduced the proportion of GABA-positive neurons by 61% relative to control, a result the authors reported within a paper whose overall conclusion was an absence of toxicity [12]. A compound that measurably shifts GABAergic differentiation in a stem-cell assay is doing something that has not been followed up.

What the evidence does not establish

The gaps here are large and should be stated before the findings, not after them.

  • No identified receptor. There is no reported high-affinity binding site for Selank. The GABA-A interaction is inferred from modulation of another ligand's binding and from downstream readouts [2, 3, 5], not from direct measurement of Selank binding to a purified target.
  • No structure. No solved conformation, no co-crystal, no NMR ensemble in the retrieved literature.
  • No resolved attribution between parent and fragments. Pentapeptide fragments are active in serum enzymology [6] and Gly-Pro reproduces much of the immune expression profile [10], so a readout observed after administering Selank cannot be assigned to the intact heptapeptide without a fragment control.
  • Narrow provenance. Much of the record traces to a small set of collaborating Russian institutes, a substantial part is published in Russian-language journals, and independent replication outside that network is scarce. This is a limitation of the evidence base, not of the individual papers.
  • Discordance between in vivo and in vitro results. The rat cortex panel showed widespread transcript changes [4]; the same panel in a human cell line showed none from Selank alone [5]. That discrepancy has not been reconciled.
  • Nothing about outcomes in humans. This guide describes receptors, assays and model systems. No claim about outcomes in humans is made or implied here. The animal readouts described above are measurements in model systems, not evidence of an effect in any other species.

Handling and stability

The strongest compound-specific stability data come from work with evenly tritium-labeled peptide, which allowed simultaneous tracking of hydrolysis products. In blood plasma, the major degradation products of TKPRPGP were the pentapeptide TKPRP, the tripeptide TKP, and the dipeptides RP and GP [7]. That is a useful and slightly deflating result. Whatever the Pro-Gly-Pro extension contributes, it does not prevent breakdown: the intact heptapeptide is cleaved in plasma, and at more than one bond — the four products listed cannot all arise from a single cut [7].

Practically, this means plasma or serum-containing media should be treated as an active degradation environment, and that fragment-aware analytics — chromatographic separation of hydrolysis products rather than a single parent-peptide measurement — are needed if the intact species is what an experiment intends to measure [7]. The same work extended to brain tissue in vivo, where concentrations of the labeled peptide and of its breakdown products were determined by liquid scintillation counting after extraction and chromatographic isolation [7]. Two of the four major plasma products, TKPRP and TKP, still contain the tuftsin motif in whole or in part, so a fragment control is not a formality — the fragments are the segment of the sequence to which the compound's presumed activity is attributed in the first place.

For the lyophilized solid, the retrieved literature offers nothing compound-specific. Cold storage of the lyophilized powder and reconstitution in a suitable aqueous buffer are ordinary handling conventions for short synthetic peptides; they are not findings from a published Selank stability study, and this guide does not present them as such.

Open questions

The questions that would most change the picture are experimental, not interpretive. Does Selank bind neuropilin-1, and is an EG00229-sensitive component present in any of its measured effects [1]? Is there a direct binding measurement for a GABA-A receptor subtype, rather than modulation of tritiated GABA binding in a membrane preparation [2]? Why is the slice electrophysiology effect flat across 1–8 μM [3], and what does that imply about the mechanism? How much of every in vivo readout survives a Gly-Pro and TKPRP fragment control [6, 7, 10]? And does anything reported here replicate in laboratories unconnected to the groups that developed the compound?

Until several of those are answered, Selank is best described as a proline-extended tuftsin analog with reproducible but indirect evidence of interaction with GABAergic signaling, quantified inhibitory activity against serum peptidases, and no identified receptor of its own.